Hjem › Akut bifenoypisk leukemi › New York
Kliniske studier for Akut bifenoypisk leukemi i New York
11 studier for Akut bifenoypisk leukemi søker deltakere på steder i New York.
Byer i New York
- New York City10 studier
- Greenburgh5 studier
- Queens4 studier
- Albany3 studier
- Syracuse3 studier
- The Bronx3 studier
Offisiell studietekst (engelsk)
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
- Memorial Sloan Kettering Cancer Center, New York
RekruttererFase 1
Alder 12 til 78 · Alle kjønn · Oppdatert 29. sep. 2026 · NCT03802695Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Albany Medical Center, Albany
- Roswell Park Cancer Institute, Buffalo
- The Steven and Alexandra Cohen Children's Medical Center of New York, New Hyde Park
- og 7 flere
RekruttererFase 2
365 Days · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06317662A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- Montefiore Medical Center, New York
RekruttererFase 1/2
30 Days · Alle kjønn · Oppdatert 16. sep. 2026 · NCT04065399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Albany Medical Center, Albany
- Maimonides Medical Center, Brooklyn
- Roswell Park Cancer Institute, Buffalo
- og 12 flere
RekruttererFase 3
365 Days – 25 Years · Alle kjønn · Oppdatert 25. aug. 2026 · NCT03959085The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Albany Medical Center, Albany
- Maimonides Medical Center, Brooklyn
- NYU Langone Hospital - Long Island, Mineola
- og 7 flere
RekruttererFase 1/2
Opp til 22 år · Alle kjønn · Oppdatert 25. aug. 2026 · NCT04726241Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- New York Medical College, Valhalla
RekruttererFase 1/2
Alder 13 til 90 · Alle kjønn · Oppdatert 6. aug. 2026 · NCT06533579Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
- Memorial Sloan- Kettering Cancer Center, New York
RekruttererFase 1
Alder 1 til 30 · Alle kjønn · Oppdatert 3. aug. 2026 · NCT06177067Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Weill Cornell Medicine - New York Presbyterian Hospital, New York
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 7. jul. 2026 · NCT07216443A Study of Revumenib and Mezigdomide in People With Leukemia
- Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities), Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
- og 1 flere
RekruttererFase 1/2
Alder 12 og eldre · Alle kjønn · Oppdatert 22. jun. 2026 · NCT07356154Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL
- Memorial Sloan Kettering Cancer Center, New York
RekruttererFase 1
Alder 12 og eldre · Alle kjønn · Oppdatert 8. jan. 2026 · NCT04872478Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Children's Hospital New York-Presbyterian, New York
- Memorial Sloan Kettering Cancer Center, New York
RekruttererFase 1
Alder 1 til 21 · Alle kjønn · Oppdatert 6. des. 2024 · NCT05476770Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.